Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis
Aim: Due to the urgent need for effective drugs to treat schistosomiasis that act through a known molecular mechanism of action, we focused on a target-based approach with the aim to discover inhibitors of a cyclic nucleotide phosphodiesterase from Schistosoma mansoni (SmPDE4A). Materials & methods: To discover new inhibitors of SmPDE4A homology models of the enzyme structure were constructed based on known human and protozoan homologs. The best two models were selected for subsequent virtual screening of our in-house chemical library. Results & conclusion: A total of 25 library compounds were selected for experimental confirmation as SmPDE4A inhibitors and after dose-response experiments, three top hits were identified. The results presented validate the virtual screening approach to identify new inhibitors for clinically relevant phosphodiesterases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 11(2019), 14 vom: 28. Juli, Seite 1703-1720 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sebastián-Pérez, Víctor [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cyclic Nucleotide Phosphodiesterases, Type 4 |
|---|
| Anmerkungen: |
Date Completed 01.06.2020 Date Revised 01.06.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2018-0592 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM29982098X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29982098X | ||
| 003 | DE-627 | ||
| 005 | 20231225101158.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2018-0592 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0999.xml |
| 035 | |a (DE-627)NLM29982098X | ||
| 035 | |a (NLM)31370708 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sebastián-Pérez, Víctor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.06.2020 | ||
| 500 | |a Date Revised 01.06.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: Due to the urgent need for effective drugs to treat schistosomiasis that act through a known molecular mechanism of action, we focused on a target-based approach with the aim to discover inhibitors of a cyclic nucleotide phosphodiesterase from Schistosoma mansoni (SmPDE4A). Materials & methods: To discover new inhibitors of SmPDE4A homology models of the enzyme structure were constructed based on known human and protozoan homologs. The best two models were selected for subsequent virtual screening of our in-house chemical library. Results & conclusion: A total of 25 library compounds were selected for experimental confirmation as SmPDE4A inhibitors and after dose-response experiments, three top hits were identified. The results presented validate the virtual screening approach to identify new inhibitors for clinically relevant phosphodiesterases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a inhibitors | |
| 650 | 4 | |a phosphodiesterase | |
| 650 | 4 | |a schistosomiasis | |
| 650 | 4 | |a virtual screening | |
| 650 | 7 | |a Phosphodiesterase 4 Inhibitors |2 NLM | |
| 650 | 7 | |a Cyclic Nucleotide Phosphodiesterases, Type 4 |2 NLM | |
| 650 | 7 | |a EC 3.1.4.17 |2 NLM | |
| 700 | 1 | |a Schroeder, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Munday, Jane C |e verfasserin |4 aut | |
| 700 | 1 | |a van der Meer, Tiffany |e verfasserin |4 aut | |
| 700 | 1 | |a Zaldívar-Díez, Josefa |e verfasserin |4 aut | |
| 700 | 1 | |a Siderius, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a de Koning, Harry P |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Dave |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Campillo, Nuria E |e verfasserin |4 aut | |
| 700 | 1 | |a Leurs, Rob |e verfasserin |4 aut | |
| 700 | 1 | |a Gil, Carmen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 11(2019), 14 vom: 28. Juli, Seite 1703-1720 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:14 |g day:28 |g month:07 |g pages:1703-1720 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2018-0592 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 14 |b 28 |c 07 |h 1703-1720 | ||